Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel

Executive Summary

After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.

You may also be interested in...



Janssen R&D’s Immunology Unit Grounded In Translational Thinking

J&J finished pulling together its disparate R&D efforts under the Janssen name in December, with a distinctive translational thread running through the entire soup-to-nuts operation. The immunology unit showcases the firm’s success with this method – the understanding of a psoriasis mechanism gained in the clinic looped back to inform research on several next generation therapies and a very broad Remicade label.

Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel

The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.

Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel

The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel